Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
Alzheimer's & Dementia ; 17(S7):e055102, 2021.
Article in English | Wiley | ID: covidwho-1664374

ABSTRACT

Background Digital technologies are creating unprecedented opportunities to improve and increase support to older people with cognitive and mental health problems, and to their family and carers. However, barriers that preclude the implementation of technology driven programs for the assessment and intervention of adults at risk of cognitive decline need to be better understood. This study investigated these outstanding issues, as well as considering the impact that the COVID-19 Pandemic has had on such barriers. Methods A sample of 105 participants completed an online survey. Their ages ranged from 18 to 92 years. Of these, 72% were female, 83% had higher education and beyond, 42% were working, 42% were retired, and 14% were unemployed. The questionnaires assessed IT experience alongside awareness, attitudes, and stigmas regarding the use of technologies, particularly those used to support cognitive and mental health. Questionnaires also explored the impact of the COVID-19 pandemic on these technology-related factors. We compared these across groups of young (n=45), middle age (n=12) and older adults (n=48). Results Relative to younger participants, older participants were less aware of, and held stronger stigmas against healthcare technologies, even though they reported more IT experience. IT awareness was associated to more positive (r=0.619, p<0.001) and less negative IT Attitudes (r=-0.271, p=0.015), more acceptability (r=-0.374, p=0.001) and receptiveness towards technologies (r=-0.610, p<0.001). Male participants appeared to be more aware of such technologies than female participants. However, relative to men, women had increased the number of ways and frequency with which they used technologies since the COVID-19 pandemic started, and older people in general felt more inclined to endorse the need to learn more about healthcare technologies. Conclusions Having more accumulated IT experience throughout our lives may not necessarily lead to better acceptance of healthcare technologies. More awareness about such specific technologies will help overcome stigmas, and challenging environments such as those imposed by the COVID-19 pandemic may lead to positive changes in perception and acceptance of such technologies. These are necessary steps towards the personalisation of healthcare technologies to support vulnerable adults at risk of dementia.

2.
Alzheimers Dement ; 17 Suppl 8: e055106, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1596805

ABSTRACT

BACKGROUND: LAC-CD has recently reported that challenges faced by LAC countries are very similar to those experienced by HIC, and that regional networks will be needed to bridge gaps. ReDLat is a US-LAC multi-partner consortium aimed at expanding dementia research in LAC. The UK-Latin America Brain Connectivity Research Network (UL-BCRN) focuses on developing new affordable EEG-based biomarkers for dementia. The Language and Brain Health Network (LBHN) integrate international multidisciplinary efforts to reveal linguistic markers of neurodegenerative diseases. METHODS: ReDLat is collecting genomic, neuroimaging, clinical, cognitive, and socioeconomic data from a first-in-class cohort anchored in six LAC (Argentina, Chile, Colombia, Brazil, Mexico, and Peru) and will compare these to US data (> 4200 participants, including 2100 controls, 1050 AD patients, and 1050 FTD patients). The 5-year project will develop innovative, harmonized, and cross-nation approaches on two of the most prevalent neurodegenerative diseases, Alzheimer's disease (AD) and Frontotemporal Dementia (FTD). The UL-BCRN currently links seven EEG labs from Colombia, Argentina, Chile, Brazil and the UK. The network's vision is to forge strong relationships between labs through which new methodologies, EEG plus multidimensional datasets, and experience will be developed and shared. The LBHN will analyze speech samples from massive AD, FTD, and control cohorts across LAC, Spain, and the US. This effort aims to identify low-cost disease-specific markers in diverse Latino and English-speaking patients. RESULTS: ReDLat will aims to reveal unique risk factors for AD and FTD in LAC compared to US populations. Data collection strategies have been adapted to face the challenges brought by the COVID-19 pandemic. The UL-BCRN has now standardised recording protocols across LAC and UK labs and is collecting data from longitudinal cohorts of patients at risk of dementia relying on novel culture-free cognitive paradigms. Preliminary LBHN data shows that, automated speech analyses can identify Latinos with AD and FTD, with good generalization across socio-biological profiles, dialects, and languages. CONCLUSION: By broadening our understanding of dementia phenotypes, risk factors, and affordable diagnostic approaches in LAC, adding new evidence on variability across HIC and LMIC, the above networks will contribute unique knowledge that will help enhance future global dementia strategies.

3.
J Alzheimers Dis ; 82(s1): S379-S394, 2021.
Article in English | MEDLINE | ID: covidwho-1045532

ABSTRACT

In comparison with other regions, dementia prevalence in Latin America is growing rapidly, along with the consequent clinical, social, and economic burden upon patients and their families. The combination of fragile health care systems, large social inequalities, and isolated clinical and research initiatives makes the coordination of efforts imperative. The Latin America and the Caribbean Consortium on Dementia (LAC-CD) is a regional organization overseeing and promoting clinical and research activities on dementia. Here, we first provide an overview of the consortium, highlighting the antecedents and current mission. Then, we present the consortium's regional research, including the multi-partner consortium to expand dementia research in Latin America (ReDLat), which aims to identify the unique genetic, social, and economic factors that drive Alzheimer's and frontotemporal dementia presentation in LAC relative to the US. We describe an extension of ReDLat which aims to develop affordable markers of disease subtype and severity using high density EEG. We introduce current initiatives promoting regional diagnosis, visibility, and capacity, including the forthcoming launch of the Latin American Brain Health Institute (BrainLat). We discuss LAC-CD-led advances in brain health diplomacy, including an assessment of responses to the impact of COVID-19 on people with dementia and examining the knowledge of public policies among experts in the region. Finally, we present the current knowledge-to-action framework, which paves the way for a future regional action plan. Coordinated actions are crucial to forging strong regional bonds, supporting the implementation of regional dementia plans, improving health systems, and expanding research collaborations across Latin America.


Subject(s)
Biomedical Research , Dementia/therapy , Caribbean Region/epidemiology , Dementia/epidemiology , Humans , International Cooperation , Latin America/epidemiology , Societies, Medical/organization & administration
SELECTION OF CITATIONS
SEARCH DETAIL